Comphya — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Comphya is pioneering a restorative neuromodulation approach to address a major unmet need in male sexual health: erectile dysfunction (ED) following prostate cancer surgery. Its lead product, CaverSTIM™, is an implantable system that delivers targeted stimulation to the cavernous nerves during the critical post-surgical recovery window, aiming to support natural nerve healing rather than just managing symptoms. The device is currently in clinical trials, with early data showing promising recovery rates, and is designed for seamless integration into existing robotic prostatectomy workflows. The company targets a significant market opportunity, as current post-surgical ED treatments are often ineffective or invasive.

UrologySexual Health

Technology Platform

Implantable, programmable neuromodulation system designed to deliver sub-sensory stimulation to pelvic/cavernous nerves to support nerve rehabilitation following surgical injury.

Opportunities

A large and growing addressable market of over 400,000 prostatectomies annually in the US and Europe, with a high rate of post-surgical ED and poor efficacy of current treatments.

A restorative, one-time intervention offers a compelling value proposition to payers by potentially reducing long-term treatment costs and improving patient quality of life, which can support favorable reimbursement.

Risk Factors

Clinical trial failure or inability to replicate promising early data in larger studies poses an existential risk.

Achieving regulatory approval (FDA, EMA) is uncertain and can be a lengthy, costly process.

Market adoption depends on convincing urologists to alter surgical workflow and securing adequate reimbursement from insurance payers for a novel, high-cost device.

Competitive Landscape

Competition includes established pharmaceutical options (PDE5 inhibitors like Viagra, which have low efficacy in this population) and other medical devices (penile implants, vacuum pumps). Comphya's primary competition is the current standard of care, which is largely palliative. Its key differentiator is its restorative, nerve-focused approach timed at the moment of surgery, a space with few direct competitors currently.

More companies in Switzerland →